Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
$1.515M
TTM
Current Assets
$162.5K
Q3 2023
Current Liabilities
$16.18M
Q3 2023
Current Ratio
1.0%
Q3 2023
Total Assets
$12.68M
Q3 2023
Total Liabilities
$16.18M
Q3 2023
Book Value
-$3.497M
Q3 2023
Cash
P/E
1.405
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2022 2021
Revenue $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2022 2021
Revenue $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2022 2021
Selling, General & Admin $1.294M $334.3K
YoY Change 287.08%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.294M $334.3K
YoY Change 287.08%
Operating Profit
YoY Change

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2022 2021
Interest Expense $9.308M $9.674M
YoY Change -3.78%
% of Operating Profit
Other Income/Expense, Net -$1.110M
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2022 2021
Pretax Income $8.014M $8.230M
YoY Change -2.63%
Income Tax
% Of Pretax Income
Net Earnings $8.014M $8.230M
YoY Change -2.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.25 $0.25

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2022 2021
Cash & Short-Term Investments $128.7K $648.3K
YoY Change -80.15%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $248.2K $324.9K
YoY Change -23.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.206M $973.2K
YoY Change 23.89%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $257.7M $255.0M
YoY Change 1.07%
Other Assets $0.00 $248.7K
YoY Change -100.0%
Total Long-Term Assets $257.7M $255.3M
YoY Change 0.97%
Total Assets $258.9M $256.2M
YoY Change
Accounts Payable $417.7K $68.70K
YoY Change 508.02%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.27M $68.70K
YoY Change 20673.23%
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $19.51M
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $19.51M
YoY Change -100.0%
Total Liabilities $14.27M $19.58M
YoY Change -27.11%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.1296 Million

About PSYENCE BIOMEDICAL LTD.

Psyence Biomedical Ltd. is a life science biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Industry: Pharmaceutical Preparations Peers: Aptose Biosciences Inc. Xenon Pharmaceuticals Inc.